The U.S. Food and Drug Administration (FDA) has granted approval to a new vaccine specifically designed to prevent chikungunya virus infection. The vaccine, called Ixchiq, is a single-dose vaccine intended for individuals at high risk of exposure to the virus.
Chikungunya is a mosquito-borne virus that has become a significant global health concern, with over 5 million cases reported in the last 15 years. The virus is commonly transmitted in tropical regions such as Africa, Southeast Asia, and the Americas, and has expanded to new areas due to climate change.
The Centers for Disease Control and Prevention (CDC) has stated that chikungunya was not a concern for Americans returning from overseas until 2006. However, the virus was found in several hundred U.S. tourists between 2006 and 2013.
Due to the severity of chikungunya and the potentially fatal complications it can cause, the French biotechnology company Valneva’s vaccine received “accelerated approval” from the FDA. The vaccine is recommended for individuals at higher risk of acquiring the virus who are at least 18 years of age.
Chikungunya cases first appeared in the U.S. in late 2014, and the virus thrives in milder climates, such as those in Florida, Texas, Puerto Rico, and the U.S. Virgin Islands. According to Dr. Peter Marks of the FDA’s Center for Biologics Evaluation and Research, the elderly and those with preexisting medical conditions are at higher risk of complications from chikungunya.
With the FDA’s approval of the chikungunya vaccine Ixchiq, health experts are hopeful that the vaccine may help prevent the spread of this viral disease which currently has no available treatments.
The vaccine, Ixchiq, is composed of a live, attenuated strain of the virus, which has the potential to induce symptoms similar to a genuine infection. The FDA has mandated a post-marketing investigation to monitor the vaccine for potentially severe adverse effects.
Throughout the approval studies, the following adverse effects were documented: headache, joint and muscle discomfort, fever, injection site tenderness, and fatigue. Only 2% of vaccine recipients experienced severe adverse reactions necessitating medical intervention, and a negligible proportion of those cases required hospitalization.
The FDA’s approval of the chikungunya vaccine Ixchiq is a significant step forward in addressing the public health concerns associated with this viral disease. The hope is that this vaccine will help protect individuals at high risk of chikungunya infection and prevent severe complications from the virus.
I have over 10 years of experience in the cryptocurrency industry and I have been on the list of the top authors on LinkedIn for the past 5 years. I have a wealth of knowledge to share with my readers, and my goal is to help them navigate the ever-changing world of cryptocurrencies.
